EDAP TMS S.A. (FOCL) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Neuraxis (NRXS) has outperformed EDAP TMS S.A. (FOCL) over the past year, gaining 128.0% versus a gain of 93.1%. EDAP TMS S.A. is the larger company by market cap ($197.8 million vs $87.0 million), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FOCL | NRXS |
|---|---|---|
| Share price | $4.19 | $6.93 |
| Market cap | $197.84M | $87.03M |
| 1-day change | +1.58% | +2.36% |
| YTD return | +27.36% | +52.64% |
| 1-year return | +93.09% | +127.96% |
| 5-year return | -30.74% | — |
| EPS (TTM) | $-1.44 | $-0.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.40 | $9.33 |
| 52-week low | $1.75 | $2.21 |
| Distance from 52-week high | -34.53% | -25.72% |
| Analyst consensus | buy | none |
| Avg. price target upside | +110.02% | +58.73% |
| Average volume | 115.89K | 108.37K |
| Shares outstanding | 47.22M | 12.56M |
| Employees | 289 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDAP TMS S.A. is about 2.3 times larger than Neuraxis by market value ($197.84M vs $87.03M).
- NRXS has outperformed FOCL by 34.9 percentage points over the past year.
About EDAP TMS S.A.
FOCL stock →EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
FOCL vs NRXS FAQ
Which is bigger, EDAP TMS S.A. or Neuraxis?
EDAP TMS S.A. (FOCL) is larger, with a market capitalization of $197.84M compared with $87.03M for Neuraxis (NRXS).
Which stock has performed better over the past year, FOCL or NRXS?
NRXS returned +127.96% over the past 12 months, compared with +93.09% for FOCL (price return, excluding dividends). Past performance does not predict future results.
Are EDAP TMS S.A. and Neuraxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.